575 abstracts found.



Results filter

Leukemic stem cell interactions with the microenvironment: Friend or foe?

Year:

Session type:

Dominique Bonnet1
1The Francis Crick Institute

Long non-coding RNAs – Messages from the dark matter of the cancer genome

Year:

Session type:

Sven Diederichs1
1University of Freiburg and German Cancer Research Center (DKFZ)

Control of cell division by long non-coding RNAs

Year:

Session type:

Duncan Odom1
1University of Cambridge

Long non-coding RNAs and the regulation of the immune response

Year:

Session type:

Mark Lindsay1
1University of Bath

Cancer prevention at the population level: Standardised packaging

Year:

Session type:

Ann McNeill1
1King’s College London and the UK Centre for Tobacco

Minimum unit pricing for alcohol: The most cost-effective cancer prevention strategy of all?

Year:

Session type:

Tim Stockwell1
1Centre for Addictions Research of British Columbia, University of Victoria

Image quantification: Do numbers help treatment stratification?

Year:

Session type:

Alan Jackson1
1University of Manchester

Therapeutic targeting of childhood medulloblastoma: strategies for blocking recurrence

Year:

Session type:

Sheila Singh1
1McMaster University

Integrating stem and progenitor cell contribution to intestinal self renewal

Year:

Session type:

Douglas Winton1
1Cancer Research UK Cambridge Institute

In search for the lacking driver genes of neuroblastoma

Year:

Session type:

Rogier Versteeg1
1Netherlands Bioinformatics Centre

Cancer prevention at the population level: Policies to prevent and treat obesity

Year:

Session type:

Susan Jebb1
1University of Oxford

HPV vaccines – how to get the maximum protection

Year:

Session type:

Margaret Stanley1
1University of Cambridge

The management of oropharynx cancer in the HPV era

Year:

Session type:

Terry Jones1
1Institute of Translational Medicine, University of Liverpool

Sentinal lymph node biopsy in head and neck cancer: Good ideas need proper trials

Year:

Session type:

Mark McGurk1
1King’s College London and Guy’s and St Thomas’ Foundation Trust

Exploiting functional information in imaging for decision making in clinical practice

Year:

Session type:

Christina Messiou1
1The Royal Marsden Hospital

Molecular imaging for targeted therapy

Year:

Session type:

Arturo Chiti1
1Humanitas University

F-18 labelled 3’-deoxy-3’-fluorothymidine (FLT) positron emission tomography (PET) imaging in patients with advanced pancreatic ductal adenocarcinoma: proof-of-concept reproducibility sub-analysis.

Year:

Session type:

Angela Lamarca1,Prakash Manoharan2,Marie-Claude Asselin3,Peter J Julyan4,Mahbubunnabi Tamal3,Ioannis Trigonis3,Mairéad G McNamara5,Richard A Hubner1,Zarni Win6,Juan W Valle5,Azeem Saleem7
1Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom,2Department of Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom,3University of Manchester Wolfson Molecular Imaging Centre (WMIC), Institute of Population Health, Manchester, United Kingdom,4Christie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, United Kingdom,5Department of Medical Oncology, The Christie NHS Foundation Trust; Institute of Cancer Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom,6Department of Radiology, Imperial College Healthcare NHS Trust, London, United Kingdom,7Department of Applications, Imanova Centre for Imaging Sciences, London, United Kingdom

THE PROMIS STUDY: DIAGNOSTIC ACCURACY OF MRI AND TRUS BIOPSY IN PROSTATE CANCER

Year:

Session type:

Louise Brown1,Hashim Ahmed2,Ahmed El-Shater Bosaily2,Gabe Rhian3,Kaplan Richard1,Yolanda Collaco-Moraes1,Katie Ward1,Richard Hindley4,Alex Freeman5,Alex Kirkham5,Robert Oldroyd6,Chris Parker7,Mark Emberton2,The PROMIS Study Group8
1MRC Clinical Trials Unit at UCL,2University College London,3University of York,4Hampshire Hospitals NHS Foundation Trust,5University College London Hospital NHS Foundation Trust,6Patient and Public Representative,7Royal Marsden Hospital,8PROMIS Collaborators

Plasma DNA for early cancer screening

Year:

Session type:

Yuk Ming Dennis Lo1
1The Chinese University of Hong Kong

Prostate cancer screening as national programme: Benefits at less harm and less cost

Year:

Session type:

Harry J. de Koning1
1Erasmus Medical Center, Rotterdam

Precision early diagnosis for oesophageal cancer

Year:

Session type:

Rebecca Fitzgerald1
1MRC Cancer Cell Unit, University of Cambridge

Genome-epigenome interplay in medulloblastoma

Year:

Session type:

Paul Northcott1
1St. Jude Children's Research Hospital

Translocations and catastrophe – chromothriptic disruption of transcription factors in ependymoma

Year:

Session type:

Richard Gilbertson1
1Cancer Research UK Cambridge Institute

Comprehensive analysis of cell-free tumour DNA in plasma and urine tracks disease burden and reveals clonal evolution in muscle invasive bladder cancer

Year:

Session type:

Christopher Smith1,Kristan van der Vos2,Keval Patel1,Charles Massie1,Francesco Marass1,James Morris1,Dana Tsui1,Florent Mouliere1,Vincent Gnanapragasam1,Tim Forshew3,Bas van Rhijn2,Nitzan Rosenfeld1,Michiel van der Heijden2
1University of Cambridge,2Netherlands Cancer Institute,3University College London

Molecular Profiling of Circulating Tumour Cells (CTCs) in Non-small cell lung cancer within the TRACERx study of Intratumoural Heterogeneity and Evolution

Year:

Session type:

Sakshi Gulati1,Francesca Chemi2,Dominic G Rothwell2,Deborah Burt2,Barbara Mesquita2,Christopher Wirth2,Gareth Wilson3,Jackie Pierce2,Ged Brady2,Charles Swanton4,Caroline Dive5
1Postdoctoral Scientist,2Cancer Research UK Manchester Institute,3The Francis Crick Institute,London, UK,4The Francis Crick Institute,London, UK and and on behalf of TRACERx consortium and Cancer Research UK Manchester/UCL Lung Cancer Centre of Excellence,5Cancer Research UK Manchester Institute and on behalf of TRACERx consortium and Cancer Research UK Manchester/UCL Lung Cancer Centre of Excellence

The contribution of genomic instability to malignant growth in Drosophila

Year:

Session type:

Cayetano Gonzalez1
1IRB-Barcelona and BIST

Aneuploidy as the large adaptive mutation: Mechanism and theory

Year:

Session type:

Rong Li1
1Johns Hopkins University School of Medicine

Rhabdovirus based oncolytic virus vaccines

Year:

Session type:

John Bell1
1Ottawa Hospital Research Institute

Systemic delivery of Enadenotucirev, a Group B oncolytic Adenovirus for the treatment of cancer

Year:

Session type:

Kerry Fisher1
1University of Oxford

How should we combine oncolytic virotherapy with other agents?

Year:

Session type:

Kevin Harrington1
1The Institute of Cancer Research

Inhibiting HOX-PBX binding in paediatric glioblastoma as a novel therapeutic treatment

Year:

Session type:

William Rogers1,Richard Morgan2,Hardev Pandha1
1University of Surrey,2University of Bradford

Deep sequencing of circulating tumour DNA for personalised cancer detection and monitoring

Year:

Session type:

Maximilian Diehn1
1Stanford University

The versatility of CTCs as a liquid biopsy: Biomarkers, biology and drug development

Year:

Session type:

Caroline Dive1
1Cancer Research UK Manchester Institute

Using circulating tumour DNA to improve the management of metastatic castration-resistant prostate cancer

Year:

Session type:

Gerhardt Attard1
1The Institute of Cancer Research

HPV drives tumor development throughout the head and neck: Improved prognosis is associated with an immune response largely restricted to the oropharynx

Year:

Session type:

Tim Fenton1,Ankur Chakravarthy1,Stephen Henderson1,Stephen Thirdborough2,Christian Ottensmeier2,Xiaoping Su3,Andrew Feber1,Matt Lechner1,Gareth Thomas2
1University College London,2University of Southampton,3MD Anderson Cancer Center, University of Texas

Targeting the androgen receptor in prostate cancer: A resilient foe

Year:

Session type:

Peter Nelson1
1Fred Hutchinson Cancer Research Center

Targeting tumour-infiltrating myeloid cells for prostate cancer therapy

Year:

Session type:

Andrea Alimonti1
1Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI)

Molecularly stratified therapeutic strategies for lethal prostate cancer

Year:

Session type:

Johann de Bono1
1The Institute of Cancer Research

Drug discovery and development to overcome cancer evolution and drug resistance

Year:

Session type:

Paul Workman1
1The Institute of Cancer Research

DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer

Year:

Session type:

Nnenna Kanu1
1UCL Cancer Institute

Mutational signatures and cancer evolution

Year:

Session type:

Serena Nik-Zainal1
1Wellcome Trust Sanger Institute

Loss of primary cilia and tissue hyperplasia associated with centrosome amplification

Year:

Session type:

David Glover1
1University of Cambridge

Cell fate imbalance in the Oesophageal Epithelium: mutant cell competition

Year:

Session type:

Maria Alcolea1
1Wellcome Trust-MRC Cambridge Stem Cell Institute

Targeting flap endonuclease 1 (FEN1) for personalization of ovarian cancer therapy

Year:

Session type:

Reem Ali1,Dorjbal Dorjsuren2,David Maloney2,Ajit Jadhav2,Anton Simeonov2,David Wilson III3,Anna Grabowska1,Emad Rakha1,Srinivasan Madhusudan1
1Division of Cancer & Stem Cells, School of Medicine, University of Nottingham, UK,2NIH Chemical Genomics Center, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, USA,3Laboratory of Molecular Gerontology, Biomedical Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224-6825, USA

Metformin increases 18F-FDG flux and inhibits fatty acid oxidation at clinical doses in breast cancer: results of a phase 0 clinical trial

Year:

Session type:

Simon Lord1,Dan Liu1,Wei-Chen Cheng1,Syed Haider1,Edoardo Gaude2,Eugene Teoh1,Neel Patel1,Tom Metcalf3,Daniel McGowan1,Ioannis Roxanis1,Zhang Qifeng4,Pankaj Roy5,Fergus Gleeson1,Alastair Thompson6,Michael Pollak7,Michael Wakelam4,Francesca Buffa1,Christian Frezza2,John Fenwick3,Adrian Harris1
1University of Oxford,2University of Cambridge,3University of Liverpool,4Babraham Institute,5Oxford University Hospitals NHS Foundation Trust,6MD Andersen Cancer Centre,7McGill University

Cancer stigma among ethnic minority women

Year:

Session type:

Laura Marlow1,Charlotte Vrinten1,Jo Waller1
1UCL

PARP trapping enhances oncolytic Reovirus cell killing in melanoma

Year:

Session type:

Joan Kyula-Currie1,Victoria Roulstone2,Richard Elliot3,Stephen Pettitt3,Dragomir Krastev3,Holly Barker3,Martin McLaughlin3,Chris Lord3,Alan Melcher3,Kevin Harrington3
1Instiitute of Cancer Research,2Institute of Cancer Research,3Institute of cancer research

Which pro-survival BCL-2 family member should be targeted for the treatment of which cancer?

Year:

Session type:

Andreas Strasser1
1The Walter and Eliza Hall Institute

Identifying human cancers to target with BCL-2 inhibition

Year:

Session type:

Anthony Letai1
1Dana-Farber Cancer Institute

Harnessing the complex relationship between mitosis and cell death

Year:

Session type:

Pascal Meier1
1The Institute of Cancer Research